DanCann Pharma is building out their entire capacity with 1, 2, and 4-Layer AEssenseGrows AEtrium Systems. With no deviations in their final developmental inspection by the Danish Medicines Agency, DanCann plans for 80M DKK (~$11M USD) shipments to Germany and Poland from the immediate production ramp from 2023 to 2025.
“After finishing 3 grow cycles in our facility for validation, we will have qualified for commercial production with zero irradiation. This is pure and perfectly sterile aeroponic cannabis flower,” said Morten Martinsen, Co-Founder and Head of Business Development, DanCann Pharma. “Everything we do, we do for the patient and aeroponics enables us to deliver unspoiled products without any contamination or degradation from the irradiation process,” Morten continued.
“The team at DanCann has crafted a completely unique grow recipe that we have not seen perfected by previous customers. Their method uses less than half the typical fertilizer content with amazing results.”, stated Michael Jorgensen, Managing Director, AEssenseGrows. “Their minimal salts aeroponic approach provides a very clean grow process with no biofilm build-up”, said Jorgensen.
DanCann has been testing many new strains over the last year with their favorites being Kush variants and several high THC hybrids and phenotypes. With standard operating procedures and workflows captured in the revolutionary Guardian Grow Manager software, DanCann has fingertip control over their entire scaled facility from one dashboard. The team expects to ramp output 20X over the next year. Already at full employment, full automation will allow the complete production ramp with minimal additional labor.
DanCann is producing pharma-grade premium cannabis for existing contracts. Current capacity, including the latest Double Deck AEtrium deliveries, is sold out through the end of 2024.
For more information:
AEssenseGrows
[email protected]
www.aessensegrows.com
For more information:
DanCann Pharma
[email protected]
www.dancann.com